Authors
Latest:
Eyes with ocular involvement from SJS/TEN mandate acute and chronic carePatients are at risk for developing severe dry eye and ocular surface disease.
Latest:
Which retirement plan is right for your practice?If you own a small business (such as a medical practice), many retirement plan alternatives are available to assist you and your eligible employees with retirement planning. To make an informed decision on which plan is right for your practice, review the differences carefully before choosing.
Latest:
A 19-year-old female has transient black spots, headachesA 19-year-old Latin female presented to the Bascom Palmer emergency room complaining of transient black spots in the right eye.
Latest:
The ins and outs of treating ‘financial cataracts’Conducting a thorough financial examination may help clinicians to see their finances as clearly as their patients see the world after cataract surgery.
Latest:
The ins and outs of treating ‘financial cataracts’Conducting a thorough financial examination may help clinicians to see their finances as clearly as their patients see the world after cataract surgery.
Latest:
The ins and outs of treating ‘financial cataracts’Conducting a thorough financial examination may help clinicians to see their finances as clearly as their patients see the world after cataract surgery.
Latest:
Study identifies key biomarkers for aflibercept response in diabetic macular edemaBrazilian researchers reveal how choroidal thickness influences treatment response in diabetic macular edema, enhancing personalized therapy strategies.
Latest:
OCT finds niche in glaucoma diagnosis, managementTechnology makes great tool, requires extra vigilance with co-existing disease
Latest:
Choroidal hypoperfusion defects in retinopathy of prematurity: A new fluorescein angiographic findingROP can be a disease that affects both the retinal and choroidal vasculatures.
Latest:
Physicians sort out pros and cons of several new IOLs on the market“Real talk” on new devices gives surgeons, patients decision-making insights
Latest:
Glaucoma: Hyperemia a common cause for medication changesHyperemia is one of the main reasons why patients with glaucoma do not adhere to or persist with their topical therapeutic regimen. Patients end up switching to another possibly more tolerable medication, and the changing of medications has significant financial implications. Latanoprost has the lowest incidence of hyperemia among the prostaglandin analogs. Patient adherence is crucial in a chronic progressive disease such as glaucoma, where non-adherence can lead to visual loss and decline in quality of life, creating societal health and economic burdens.
Latest:
ASCRS/ASOA annual meeting setting sail to San DiegoThe 2019 annual meetings of the American Society of Cataract and Refractive Surgery and the American Society of Ophthalmic Administrators will be held May 3 to 7 in San Diego.
Latest:
ARVO to launch new journalThe Association for Research in Vision and Ophthalmology is launching a third journal, Translational Vision Science & Technology, an online-only, peer-reviewed journal emphasizing multidisciplinary research that bridges the gap between basic research and clinical care.
Latest:
Convey the need but don't forget the funToday's successful physicians not only understand the role of branding in the practice management mix but also realize that establishing, burnishing, and communicating the practice's positioning is essential.
Latest:
Genentech decision expands access to bevacizumabGenentech has agreed to allow its wholesale distributors to ship its bevacizumab (Avastin) to compounding pharmacies or other locations of a physician's choice.
Latest:
Improving surgical outcomes for pediatric patientsTechniques, technologies minimize complications and guide counseling, care.
Latest:
Style versus substanceAny asset protection plan that will truly stand up if challenged must have economic substance.
Latest:
Emerging technology aids diabetic retinopathy screeningOphthalmologists should take a proactive approach toward the screening, management, and early treatment of diabetic retinopathy.
Latest:
Dry eye brimming with innovationThe acceleration of research focused on dry eye over the past several decades has led to an increase in knowledge regarding the pathophysiology of the disease.
Latest:
Specialists offer pearls for physicians’ financial healthChanges in health care industry can affect the way ophthalmologists plan their finance.
Latest:
Association between the triglyceride-glucose index and central retinal artery occlusionThe investigators set out to identify a correlation between the TyG index in CRAO in patients who had been newly diagnosed with the disease.
Latest:
What patients need to know about cataract surgeryUday Devgan, MD, FACS, of Devgan Eye Surgery in Los Angeles and Beverly Hills, CA, answers a few key questions his patients have asked when considering cataract surgery.
Latest:
Biologic agents treat ocular inflammatory diseaseEditor's Note: As defined by the FDA, the term "biologics" refers to a wide range of products that includes vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins, such as monoclonal antibodies and antibody fragments.
Latest:
Pearls for building the corneal inlay patient base in your practiceCombining LASIK, corneal inlays hits refractive ‘sweet spot’ for many patients
Latest:
Institute marks 45th anniversary with new department chiefThe institute will continue to focus on the development of the clinician-scientist model.
Latest:
Crowds for hire: Finding the voice of patient needsMedication compliance and regular exams are important to maintaining healthy vision. Turn your patients into a loyal ‘fan base’ with these consumer-friendly tips.
Latest:
Facial anatomy key to optimal use of botulinum toxinBotulinum toxin type A effect is usually seen 2 to 3 days following injection, with maximal effect at approximately 2 weeks. Touch-ups are not recommended until 2 weeks have passed.
Latest:
Mechanical aid assists in administration of drugChicago-The expense of latanoprost (Xalatan, Pfizer Ophthalmics) treatment may be driven down with the use of a relatively new device that assists patients in proper administration of the eye drops, according to a research team led by Sriram Sonty, MD, FACS, clinical associate professor, University of Illinois, Chicago Eye Center.
